Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
SIMVASTATIN (UNII: AGG2FN16EV) (SIMVASTATIN - UNII:AGG2FN16EV)
Mylan Institutional Inc.
SIMVASTATIN
SIMVASTATIN 10 mg
ORAL
PRESCRIPTION DRUG
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets are indicated to: - Reduce the risk of total mortality by reducing CHD deaths. - Reduce the risk of non-fatal myocardial infarction and stroke. - Reduce the need for coronary and non-coronary revascularization procedures. Simvastatin tablets are indicated to: - Reduce elevated total cholesterol (to
Simvastatin tablets USP are supplied as follows: 10 mg: Light-pink, round, convex, film-coated tablets, debossed “7153” on one side and “TV” on the other side. They are supplied as follows: NDC 51079-454-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). 20 mg: Tan, round, convex, film-coated tablets, debossed “7154” on one side and “TV” on the other side. They are supplied as follows: NDC 51079-455-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). 40 mg: Red, round, convex, film-coated tablets, debossed “7155” on one side and “TV” on the other side. They are supplied as follows: NDC 51079-456-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Abbreviated New Drug Application
SIMVASTATIN- SIMVASTATIN TABLET, FILM COATED MYLAN INSTITUTIONAL INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE SIMVASTATIN TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR SIMVASTATIN TABLETS. SIMVASTATIN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1991 INDICATIONS AND USAGE Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2, 1.3) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4) DOSAGE AND ADMINISTRATION Dose range is 5 to 40 mg/day. ( 2.1) Recommended usual starting dose is 10 or 20 mg once a day in the evening. ( 2.1) Recommended starting dose for patients at high risk of CHD is 40 mg/day. ( 2.1) Due to the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of simvastatin tablets should be restricted to patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. ( 2.2) Patients who are currently tolerating the 80 mg dose of simvastatin tablets who need to be initiated on an interacting drug that Olvassa el a teljes dokumentumot